PA-KNOPP-BIOSCIENCES
7.3.2017 12:02:04 CET | Business Wire | Press release
Knopp Biosciences LLC today announced the publication of results from multiple clinical trials demonstrating the eosinophil-lowering effects of dexpramipexole, a small molecule treatment in development for eosinophil-associated diseases.
Eosinophils are white blood cells associated with inflammation in numerous diseases, including hypereosinophilic syndromes (HES), eosinophilic asthma, and chronic rhinosinusitis with nasal polyps. Dexpramipexole is an orally available small molecule in development for the treatment of HES, with a Phase 2 trial in eosinophilic asthma also planned to begin in the second half of 2017.
“The totality of the evidence to date, across multiple clinical studies in multiple indications, demonstrates that dexpramipexole is a targeted eosinophil-lowering agent with eosinophil-lowering effects equal to or greater than monoclonal antibodies against interleukin-5 or its receptor,” said Michael Bozik, M.D., president and CEO of Knopp Biosciences. “These newly released data strengthen our plans to rapidly advance dexpramipexole as a novel non-steroidal, orally available treatment in both HES and eosinophilic asthma.”
In a poster presentation (abstract #202) to the 2017 American Academy of Allergy and Immunology (AAAAI) in Atlanta, Georgia, data were reported from a Knopp-sponsored multicenter study of dexpramipexole in chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilia. The Phase 2 trial was an open label study of dexpramipexole 300 mg/day in 16 CRSwNP subjects with baseline blood absolute eosinophil counts (AEC) ≥0.30x109 /L and polyp eosinophilia. Co-primary endpoints examined were change in AEC and change in total polyp score (TPS) from baseline to end of study. Change in nasal polyp eosinophil counts from baseline to end of study was an exploratory endpoint.
Baseline AEC was 0.525x109 /L. AEC at month 6 was 0.031x109 /L, a 94% reduction (p<0.001). In the 12 subjects with baseline and end-of-study polyp biopsies, polyp tissue eosinophilia was reduced from 234 eosinophils per high-powered field at baseline to 5 eosinophils per high-powered field at end of study, a 97% reduction (p=0.001). There was no significant reduction in TPS despite profound reductions in blood and nasal polyp eosinophils. Dexpramipexole was well tolerated with no drug-related serious adverse events. Five subjects elected to continue on a long-term extension study.
The magnitude of eosinophil lowering (>90%) by dexpramipexole further strengthen the rationale for its development in eosinophilic asthma, in which eosinophil lowering by anti-IL5 and anti-IL5Rα antibodies has been demonstrated to reduce exacerbations, as well as in other eosinophil-associated diseases.
Knopp also announced the publication of significant eosinophil-lowering effects of dexpramipexole in earlier Phase 2 and Phase 3 clinical trials in amyotrophic lateral sclerosis (ALS). The results were published in the journal Blood Cells, Molecules and Diseases . The article abstract is available at this link .
In the Phase 2 clinical trial, a double-blind, placebo-controlled, dose-ranging study of dexpramipexole in 102 ALS subjects, highly significant reductions from baseline in mean blood eosinophils were observed in the 150 mg/day (-69.9%, p < 0.001) and 300 mg/day (-43.5%, p < 0.001) dose groups, respectively, at month 3. The significant eosinophil-lowering effect of dexpramipexole 300 mg/day was confirmed in the Phase 3 clinical trial, a double-blind study of 942 ALS subjects randomized 1:1 to placebo or dexpramipexole 300 mg daily treatment for up to 18 months. At month 6, the change from baseline in blood eosinophil counts was − 69.1% in the dexpramipexole-treated group (p < 0.001), an effect that persisted through the end of study.
As previously announced , dexpramipexole has also demonstrated significant eosinophil lowering and corticosteroid sparing in an open label trial in hypereosinophilic syndromes.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need in clearly defined patient populations. Our clinical-stage small molecule, dexpramipexole, will be entering late-stage clinical studies in hypereosinophilic syndromes and Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene. For more information, visit www.knoppbio.com .
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs for dexpramipexole. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170307005329/en/
Contact:
Knopp Biosciences LLC
Tom Petzinger, +1-412-488-1776
tom@knoppbio.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Opens Its First Forest Lab in Brazil's Atlantic Forest to Advance Fragrance and Beauty Innovation18.11.2026 12:30:00 CET | Press release
New lab at Legado das Águas, Brazil’s largest private Atlantic Forest reserve, connects biodiversity with scientific discovery and innovation in perfumery and beauty. IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today opened its first Forest Lab at Legado das Águas, Brazil's largest private Atlantic Forest reserve. The lab is the next step in the bioprospecting partnership IFF announced in August 2025 with Reservas Votorantim (rV), the green economy division of Brazilian investment firm Votorantim SA, which manages the reserve. Spanning 31,000 hectares and home to nearly 1,000 plant species, Legado das Águas now hosts biodiversity research, scent discovery, perfumery and beauty innovation in one place, while supporting rV's conservation work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117495933/en/ A scientist in the new IFF Brazil Forest Lab at Legado das Águas, the country’s
72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns18.11.2026 09:01:00 CET | Press release
Organizations with embedded network resilience report outage costs $6 million lower, Opengear research finds Nearly three in four organizations (72%) have delayed, scaled back or paused an AI or edge project in the past 12 months over concerns about network resilience, according to new research from Opengear, a Digi International company (NASDAQ: DGII) (www.digi.com). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118888190/en/ 72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns The same research shows how the best-prepared organizations fare. Organizations with embedded network resilience, meaning they can reach and recover critical infrastructure when the primary network is down, reported estimated average outage costs $6 million lower over the past 12 months than organizations with less developed resilience capabilities ($12.4 million versus $18.8 million). The advanta
SWISSto12 Selects DLR GSOC as Flight Dynamics Software Partner to Support Upcoming HummingSat Satellite Missions18.11.2026 09:00:00 CET | Press release
Agreement underscores SWISSto12’s expanding relationship with key players in Germany’s space ecosystem SWISSto12, one of the world’s fastest-growing satellite and aerospace companies, today announced it has contracted the German Aerospace Center (DLR) to serve as the company’s primary flight dynamics software provider across its upcoming HummingSat GEO satellite missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118073472/en/ SWISSto12 has selected DLR’s GSOC as its primary flight dynamics software provider for upcoming HummingSat GEO satellite missions. Under this agreement, GSOC will deliver capabilities that span orbit determination, propagation, manoeuvre planning and calibration, orbit events, antenna pointing, and long-term mission analysis. The collaboration is designed to standardise flight dynamics across SWISSto12 programmes, using a heritage European solution integrated into the company’s ground segment a
Abbove Brings European Wealth Planning Into the AI Era18.11.2026 08:05:00 CET | Press release
With the new Abbove MCP connector, advisors can now securely connect their AI tools to their clients’wealth data held in Abbove. Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors
Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 06:00:00 CET | Press release
The AI adoption race is giving way to a bigger divide: firms that redesign work and those that fall behind Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
